Probiotic-based Anticancer Immunity In Hepato-cellular Carcinoma (liver Cancer)-Reference-Cited by-同舟云学术

Probiotic-based Anticancer Immunity In Hepato-cellular Carcinoma (liver Cancer)

Published:2023-05-11 Issue: Volume: Page:189-210
ISSN:
Container-title:Probiotics in Anticancer Immunity
language:
Short-container-title:

Author:

Shah Firdosh¹,Kumar Dwivedi Mitesh¹

Affiliation:

1. Uka Tarsadia University,Faculty of Science,Surat,India,

Abstract

One of the most dreaded outcomes of chronic liver illness is hepatocellular carcinoma (HCC), and it is the most prevalent primary liver cancer. The gut-liver axis has been shown to play a key role in the emergence of chronic liver disorders, including HCC, in recent experimental and clinical studies. The altered gut microbiota is becoming well recognised as an important factor in the progression of chronic liver disorders, such as HCC. Probiotics administration has been proposed as a new, safe and cost-effective strategy for preventing or treating HCC. Probiotics' ability to bind carcinogens, regulation of gut microbiota, improvement of intestinal barrier integrity, and immunomodulation are the mechanisms by which they exert anticancer benefits. This chapter discusses the alterations in gut microbiota linked to HCC and the implications of probiotics and prebiotics for anticancer mechanisms towards HCC.<br>

Publisher

BENTHAM SCIENCE PUBLISHERS

Reference120 articles.

1. Llovet J.M.; Zucman-Rossi J.; Pikarsky E.; Sangro B.; Schwartz M.; Sherman M.; Gores G.; Hepatocellular carcinoma. Nat Rev Dis Primers 2016,2(1),16018

2. Villanueva A.; Hepatocellular Carcinoma. N Engl J Med 2019,380(15),1450-1462

3. International Agency for Research on Cancer. GLOBOCAN 2018. IARC (2020).

4. Akinyemiju T.; Abera S.; Ahmed M.; Alam N.; Alemayohu M.A.; Allen C.; Al-Raddadi R.; Alvis-Guzman N.; Amoako Y.; Artaman A.; Ayele T.A.; Barac A.; Bensenor I.; Berhane A.; Bhutta Z.; Castillo-Rivas J.; Chitheer A.; Choi J.Y.; Cowie B.; Dandona L.; Dandona R.; Dey S.; Dicker D.; Phuc H.; Ekwueme D.U.; Zaki M.E.S.; Fischer F.; Fürst T.; Hancock J.; Hay S.I.; Hotez P.; Jee S.H.; Kasaeian A.; Khader Y.; Khang Y.H.; Kumar G.A.; Kutz M.; Larson H.; Lopez A.; Lunevicius R.; Malekzadeh R.; McAlinden C.; Meier T.; Mendoza W.; Mokdad A.; Moradi-Lakeh M.; Nagel G.; Nguyen Q.; Nguyen G.; Ogbo F.; Patton G.; Pereira D.M.; Pourmalek F.; Qorbani M.; Radfar A.; Roshandel G.; Salomon J.A.; Sanabria J.; Sartorius B.; Satpathy M.; Sawhney M.; Sepanlou S.; Shackelford K.; Shore H.; Sun J.; Mengistu D.T.; Topór-Madry R.; Tran B.; Ukwaja K.N.; Vlassov V.; Vollset S.E.; Vos T.; Wakayo T.; Weiderpass E.; Werdecker A.; Yonemoto N.; Younis M.; Yu C.; Zaidi Z.; Zhu L.; Murray C.J.L.; Naghavi M.; Fitzmaurice C.; The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level. JAMA Oncol 2017,3(12),1683-1691

5. Yu L.X.; Schwabe R.F.; The gut microbiome and liver cancer: mechanisms and clinical translation. Nat Rev Gastroenterol Hepatol 2017,14(9),527-539